Bayer's Mason joins GE service effort
Former Agfa technical imaging chief Caren Mason has left a newposition at Agfa's parent company Bayer for a job in the serviceorganization of GE Medical Systems. Mason had been in the Bayerposition for only a matter of weeks before she accepted the
Former Agfa technical imaging chief Caren Mason has left a newposition at Agfa's parent company Bayer for a job in the serviceorganization of GE Medical Systems. Mason had been in the Bayerposition for only a matter of weeks before she accepted the jobwith the Milwaukee company.
Mason had led Agfa's Ridgefield Park, NJ, technical imaging divisionsince 1994, overseeing the unit's development into one of theindustry's most successful suppliers of PACS equipment. She waspromoted last month to a new position at Bayer as senior vicepresident of Bayer Corporate Healthcare (SCAN 6/19/96).
At GE, Mason has been named general manager of the southeasternservice zone and will be based in Atlanta, according to Tom Dunham,vice president and general manager of GE's service division.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
GE HealthCare Unveils Enhanced LesionID Pro at SNMMI Conference
Published: June 21st 2025 | Updated: June 21st 2025Emphasizing a zero-click experience, the updated LesionID Pro software, to be introduced at the SNMMI conference, reportedly provides AI-powered automated insights into whole-body tumor burden with PET and SPECT imaging.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.
